BIONTECH SE-ADR (BNTX)

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests.

5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Here are three no-brainer biotech stocks to buy with $200 right now. Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere. You can scoop up a share of BioNTech for less than $120 at the time of this writing.

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

Here are two healthcare stocks to buy hand over fist and one to avoid. In the third quarter of 2021, BioNTech (NASDAQ: BNTX) raked in revenue of over 6 billion euros (around $6.9 billion based on the then-current exchange rate). Fast forward to Q3 of 2024, and BioNTech's revenue was only 1.24 billion euros (roughly $1.3 billion), due to the steep decline in demand for the COVID-19 vaccine the company markets with its partner Pfizer.

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

2 No-Brainer Stocks to Buy Before the End of 2024

Why Is BioNTech Stock Trading Higher On Friday?

On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE (NASDAQ:BNTX). The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting in Singapore and showed encouraging antitumor activity alongside a manageable safety profile in heavily pretreated patients with locally advanced or metastatic solid tumors. The ongoing Phase 1/2a trial analysis included 277 part

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

BNT324/DB-1311 showed encouraging antitumor activity and a manageable safety profile in a Phase 1/2a clinical trial in heavily pretreated patients with locally...

5 Top Stocks to Buy in December

Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock.

5 Top Stocks to Buy in December

Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock.

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

BioNTech Stock Got A IBD RS Rating Lift

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

BioNTech to Acquire Biotheus to Boost Oncology Strategy

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x...

BioNTech kündigt Übernahme von Biotheus zur beschleunigten Umsetzung der Onkologie-Strategie an

Übernahme soll globale Umsetzung von BioNTechs Onkologie-Strategie unterstützen und die weltweiten Rechte an BNT327/PM8002 sichern; der Kandidat ist ein...

BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript

BNTX earnings call for the period ending September 30, 2024.

BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook

The company now expects sales to come in at the lower end of its previous guidance.

BioNTech Beats Expectations, Gives Update on Cancer Drugs

BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate...

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2024 sowie Informationen zur Geschäftsentwicklung

Veröffentlichung klinischer Daten für mehrere Produktkandidaten aus verschiedenen Wirkstoffklassen, einschließlich des bispezifischen Antikörperkandidaten...